Navigation Links
Trubion Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
Date:9/8/2009

SEATTLE, Sept. 8 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today that executives will present a corporate update at the upcoming Morgan Stanley Global Healthcare Conference in New York City. Peter Thompson, M.D., FACP, president, chief executive officer and chairman of the board of directors, and Michelle Burris, senior vice president and chief financial officer, are scheduled to present on Monday, Sept. 14 at 8 a.m. EDT. The presentation will be available via audio webcast at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=TRBN&item_id=2400648.

(Logo:http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The Company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP, therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the Company's Wyeth collaboration. Trubion's product pipeline also includes TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies developed under the company's Facet Biotech collaboration. In addition to Trubion's current clinical stage product pipeline, the Company is also developing its multi-specific SCORPION technology, both for targeting cell-surface molecules like CD79b and HLA-DR, as well simultaneously neutralizing soluble ligands like TNF and IL-6. More information is available in the investors section of Trubion's website: http://investors.trubion.com/index.cfm.

TRBN-G

    Contact:
    Jim DeNike
    Senior Director, Corporate Communications
    Trubion Pharmaceuticals, Inc.
    (206) 838-0500
    jdenike@trubion.com
   http://www.trubion.com

    Waggener Edstrom Worldwide Healthcare
    Amy Petty
    Senior Account Executive
    (617) 576-5788
    amyp@waggeneredstrom.com


'/>"/>
SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Trubion Announces Dates for Second Quarter and First Half 2009 Earnings Conference Call
2. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
3. Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
4. Trubion Announces Dates for First-Quarter 2009 Earnings Conference Call
5. Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting
6. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
7. Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
8. Trubion Announces Presentations at Upcoming Investor Conferences
9. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
10. Trubion Announces Presentations at Upcoming Investor Conferences
11. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... Cambridge Semantics, the leading ... today announced that it has been named to The Silicon Review’s “20 Fastest Growing ... other markets, Cambridge Semantics serves the needs of end users facing some of the ...
(Date:4/27/2016)... SPRING, Md. and RESEARCH TRIANGLE ... Therapeutics Corporation (NASDAQ: UTHR ) announced today ... Executive Officer, of United Therapeutics will provide an overview ... Bank 41 st Annual Health Care Conference. ... 5, 2016, at 10:00 a.m. Eastern Time, and can ...
(Date:4/27/2016)... ... ... Global Stem Cells Group CEO Benito Novas announced that Duncan Ross, Ph.D. ... Labs in Miami. , In 2004, Ross received his Ph.D. in Immunology from the ... the suppression of graft vs. host disease (GVHD) under UM Professor Robert Levy Ph.D. ...
(Date:4/26/2016)... ... April 26, 2016 , ... BaseHealth , the ... the company as Chief Business Officer. Arianpour, a genomics pioneer and visionary commercial ... was most recently Chief Commercial Officer of Pathway Genomics. He has held senior ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:3/29/2016)... BOCA RATON, Florida , March 29, 2016 /PRNewswire/ ... ("LegacyXChange" or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect ... Synthetic DNA in ink used in a variety of ... preventing theft. Buyers of originally created collectibles from athletes ... authenticity through forensic analysis of the DNA. ...
(Date:3/18/2016)... --> --> Competitive Landscape Analysis ... Physical infrastructure and Perimeter Surveillance & Detection Systems ... and the continuing migration crisis in the Middle ... led visiongain to publish this unique report, which is crucial ... & security companies in the border security market and the ...
Breaking Biology News(10 mins):